Role of tenascin in human immunoglobulin A nephropathy

Journal of International Medical Research

Volumn 25, Issue 5, 1997, Pages 247-254

  Masaki, T ^a   Yorioka, N ^a   Taniguchi, Y ^a   Ogawa, T ^a   Naito, T ^a   Nishiki, T ^a   Harada, Y ^a   Yamakido, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Activity index; Chronicity index; Immunoglobulin A nephropathy; Tenascin

Indexed keywords

STEROID; TENASCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; GLOMERULUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY BIOPSY; MALE; SCHOOL CHILD; SCORING SYSTEM; STAINING; STEROID THERAPY; TREATMENT PLANNING;

EID: 0030783418     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500502     Document Type: Article

References (23)

1. Julian BA, Waldo FB, Rifai A, et al: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 1988; 84: 129-132.
2. Niemir ZI, Stein H, Noronha IL, et al: PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995; 48: 1530-1541.
3. D'Amico G: Influence of clinical and histological features on actuarial survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-323.
4. Chauveau D, Droz D: Follow up evaluation of the first patients with IgA nephropathy described at Necker Hospital. IgA nephropathy. The 25th year. Contrib Nephrol 1993; 104: 1-5.
5. Alamartine E, Sabatier JC, Guerin C, et al: Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis 1991; 18: 12-19.
6. D'Amico G, Ragni A, Gandini E, et al: Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993; 104: 6-13.
7. Freedman BI, Spray BJ, Heise ER: HLA associations in IgA nephropathy and focal and segmental glomerulonephritis. Am J Kidney Dis 1994; 23: 352-357.
8. Andreoli SP, Bergstein JM: Treatment of severe IgA nephropathy in children. Pediatr Nephrol 1989; 3: 248-253.
9. Kobayashi Y, Fujii K, Hiki Y, et al: Steroid therapy of IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12-17.
10. Kobayashi Y, Hiki Y, Fujii K, et al: Moderately proteinuric IgA nephropathy. Prognostic prediction of individual clinical cases and steroid therapy in progressive cases. Nephron 1989; 53: 250-256.
11. Waldo FB, Wyatt RJ, Kelly DR, et al: Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 1993; 7: 529-532.
12. Kobayashi Y, Hiki Y, Kokubo T, et al: Steroid therapy during the early stage of progressive IgA nephropathy. Nephron 1996; 72: 237-242.
13. Erickson HP, Bourdon MA: Tenascin: an extracellular matrix protein prominent in specialized embryonic tissue and tumors. Annu Rev Cell Biol 1989; 5: 71-92.
14. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, et al: Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986; 47: 131-139.
15. Truong LD, Pindur J, Barrios R, et al: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994; 45: 201-210.
16. Assad L, Schwartz MM, Virtanen I, et al: Immunolocalization of tenascin and cellular fibronectins in diverse glomerulopathies. Virchows Arch B Cell Pathol 1993; 63: 307-316.
17. Chiquet M: Tenascin: an extracellular matrix protein involved in morphogenesis of epithelial organs. Kidney Int 1992; 41: 629-631.
18. Truong LD, Foster SV, Barrios R, et al: Tenascin is an ubiquitous extracellular matrix protein of human renal inter-stitium in normal and pathologic conditions. Nephron 1996; 72: 579-586.
19. Taniguchi Y, Yorioka N, Oda H, et al: Platelet-derived growth factor, interleukin (IL)-1β, IL-6, IL-6R and tumor necrosis factor-α in IgA nephropathy. Nephron 1996; 74: 652-660.
20. Truong LD, Pindur J, Foster SV, et al: Tenascin expression in nephrogenesis and in normal or pathologic features and functional implications. Nephron 1996; 72: 499-506.
21. Gould VE, Martinez-Lacabe V, Virtanen I, et al: Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 1992; 67: 71-79.
22. Wallace DJ, Goldfinger D, Savage G, et al: Predictive value of clinical, laboratory, pathologic and treatment variables in steroid/immunosuppressive resistant lupus nephritis. J Clin Apheresis 1988; 4: 30-34.
23. Johnson RJ: Role of cytokines and growth factors in glomerulonephritis: a chance for future therapeutic intervention. Nephron 1996; 73: 506-514.